Imran Poonawala, DO
Internal Medicine · Houston, TXNPI 1548656283
Payments from drug & device makers
Across 171 payments — averaging $17.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$515
- Johnson & Johnson$313
- Shionogi Inc$216
- Novartis$194
- Novo Nordisk$133
- Merck$133
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,87098%
- Education$532%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 29 | $515 |
| Johnson & Johnson | 17 | $313 |
| Shionogi Inc | 10 | $216 |
| Novartis | 10 | $194 |
| Novo Nordisk | 8 | $133 |
| Merck | 11 | $133 |
| Mylan Specialty L.p. | 6 | $131 |
| Amgen | 8 | $122 |
| Avanir Pharmaceuticals, Inc. | 7 | $107 |
| Lilly USA, LLC | 6 | $106 |
| AstraZeneca | 7 | $104 |
| Sunovion Pharmaceuticals Inc. | 8 | $101 |
| Arbor Pharmaceuticals, Inc. | 5 | $90 |
| Pfizer | 4 | $89 |
| Otsuka America Pharmaceutical, Inc. | 4 | $73 |
| Philips North America LLC | 4 | $53 |
| AbbVie | 3 | $43 |
| Abbott | 2 | $41 |
| Astellas Pharma US Inc | 2 | $37 |
| Eisai Inc. | 2 | $35 |
| Bayer | 2 | $33 |
| Dexcom, Inc. | 2 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $30 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Nevro Corp. | 1 | $20 |
| Electromed, Inc. | 1 | $19 |
| Boston Scientific | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Sun Pharmaceutical Industries Inc. | 1 | $13 |
| Lundbeck LLC | 1 | $13 |
| Antares Pharma, Inc. | 1 | $12 |
How this compares
$2,923 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 104 | $156,673 |
| EliquisApixaban | 83 | $78,130 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $41,729 |
| JardianceEmpagliflozin | 28 | $39,148 |
| TrulicityDulaglutide | 27 | $34,205 |
| XareltoRivaroxaban | 23 | $20,572 |
| MyrbetriqMirabegron | 18 | $18,584 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $16,682 |
| JanuviaSitagliptin Phosphate | 19 | $14,747 |
| Atorvastatin Calcium | 701 | $6,189 |
| Gabapentin | 239 | $5,244 |
| Wixela InhubFluticasone Propion/Salmeterol | 14 | $5,021 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $4,928 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 114 | $4,554 |
| Buprenorphine | 13 | $3,781 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $133 | $156,673104 claims |
| PfizerEliquis | $89 | $78,13083 claims |
| GSKTrelegy Ellipta | $515 | $41,72939 claims |
| Boehringer IngelheimJardiance | $15 | $39,14828 claims |
| Lilly USA, LLCTrulicity | $106 | $34,20527 claims |
| Johnson & JohnsonXarelto | $313 | $20,57223 claims |
| Astellas Pharma US IncMyrbetriq | $37 | $18,58418 claims |
| MerckJanuvia | $133 | $14,74719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Houston
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Aung NaingHouston$30.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Nicholas ShortHouston$17.6M
- Isabella GlitzaHouston$14.8M
- Murtaza MussajiHouston$13.1M
- Hussein TawbiHouston$12.6M
- Hans LeeHouston$11.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.